Browse studies
Find your next paid study
4 recruiting studies matching your filters
Deliver Insights in Hypertrophic Cardiomyopathy and Observational Outcomes in Real World: United States and European Prospective Registry Study
This registry evaluates patient characteristics, real-world treatment patterns, and short- and long-term outcomes in a population of patients in the United Sta…
Obstructive Hypertrophic Cardiomyopathy
Estimated
~$10 – $1,125
Bristol-Myers SquibbNCT05489705
Phase 2
A Global Phase 2b, Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Ninerafaxstat in Patients With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy - FORTITUDE-HCM
FORTITUDE-HCM is a global, multicenter, double-blind, parallel-group, placebo-controlled Phase 2b study that will assess the efficacy and safety of ninerafaxst…
Non-obstructive Hypertrophic Cardiomyopathy
Estimated
~$10 – $8,750
Imbria Pharmaceuticals, Inc.NCT07023614
Coronary Flow Reserve in oHCM Patients Before and After 12 Months of Standard-of-care Mavacamten Treatment as Assessed by PET/CT
The goal of this observational study is to measure the effect of mavacamten treatment on blood flow in the heart muscle (myocardium) in patients with obstructi…
Obstructive Hypertrophic Cardiomyopathy
Estimated
~$10 – $1,125
Michael AyersNCT06023186
Real-World Camzyos Patient Reported OutcoMes Through PAtient SurveyS in Hypertrophic CardioMyopathy (COMPASS-HCM): A Prospective Longitudinal Study
This real-world study will assess changes in health status among participants with symptomatic obstructive hypertrophic cardiomyopathy who are treated with mav…
Obstructive Hypertrophic Cardiomyopathy
Estimated
~$10 – $1,125
Bristol-Myers SquibbNCT06551129